Media stories about DURECT (NASDAQ:DRRX) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DURECT earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.7409577427454 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of DURECT (DRRX) remained flat at $$1.08 during trading hours on Monday. 444,968 shares of the stock traded hands, compared to its average volume of 723,350. DURECT has a 12 month low of $0.74 and a 12 month high of $2.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.57 and a current ratio of 1.67.

DURECT (NASDAQ:DRRX) last announced its quarterly earnings data on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.09. The firm had revenue of $20.75 million for the quarter, compared to analysts’ expectations of $5.09 million. DURECT had a negative return on equity of 419.65% and a negative net margin of 62.57%. sell-side analysts anticipate that DURECT will post -0.14 EPS for the current fiscal year.

A number of research firms recently commented on DRRX. Stifel Nicolaus cut DURECT from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. ValuEngine raised DURECT from a “sell” rating to a “hold” rating in a research note on Tuesday, September 26th. Laidlaw reduced their target price on DURECT from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Finally, HC Wainwright cut DURECT from a “buy” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday, October 20th.

COPYRIGHT VIOLATION NOTICE: “DURECT (DRRX) Receives Daily News Impact Score of 0.12” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/12/04/durect-drrx-receives-daily-news-impact-score-of-0-12.html.

DURECT Company Profile

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Insider Buying and Selling by Quarter for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT Corporation and related companies with MarketBeat.com's FREE daily email newsletter.